First Rounders: John Maraganore

{}

Our News

May 9, 2018

Alnylam Pharmaceuticals

Our CEO John Maraganore, Ph.D. recently chatted with the Nature Biotechnology Podcast about his path into science, through research and ultimately into biotech. He also talks about why RNAi (RNA interference) was such a strong pull for him to join Alnylam and the challenges of developing an entirely new, innovative class of medicines.

Nature Biotechnology Podcast

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site